Skip to main content
University of Virginia Logo
UVA Today

UVA Today Supplemental

  • Subscribe

Main navigation

Main menu

  • All News
  • Arts & Culture
  • Business & Government
  • Research & Discovery
  • Student Experience
  • University News
  • Home
  • Subscribe

UVA Today Branding

UVA Today Branding

  • The Bigger Picture
  • Faculty Spotlight
  • Hoo? What? Where?
  • Inside UVA Podcast
  • The Music Beat
  • So Hoos Asking?
  • UVA In The News
  • Video
UVA Logo

Research & Discovery

A UVA Engineering rover model
Research & Discovery
Researchers Explore Laser-Beaming Energy for Lunar and Terrestrial Needs
Engineering professor Mool Gupta and a student team are researching the use of laser technology to move energy on the moon.
A graphical representation of the Milky Way being warped
Research & Discovery
A Warp in the Milky Way Linked to Galactic Collision
Using tools that offer them an unprecedented view of our galaxy’s stars, UVA astronomers say a phenomenon warping the edges of the Milky Way is the result of an intergalactic event that happened 3 billion years ago.
Illustration of a syringe drawing up a covid-19 vaccine
Research & Discovery
Antibody Cocktail Prevents Symptomatic COVID-19 Infections, Early Results Suggest
UVA Health is among the test sites examining effects in people exposed to the coronavirus.
Quantum dots are synthesized in a flask
Research & Discovery
Creating a Clearer Picture: UVA Team Improving Weapons Screening at U.S. Ports
Two UVA professors are using the same technology that produces colored glass to help the Department of Homeland Security keep America safe.
Dr. Jayakrishna Ambati looking into a ophthalmoscope
Research & Discovery
Common HIV Drugs May Help Prevent Leading Cause of Vision Loss, Study Finds
A surprising DNA discovery from scientists including UVA’s Dr. Jayakrishna Ambati points to a potential treatment for macular degeneration.
Powerlines touching the ground and poles leaning over due to a Hurricane
Research & Discovery
Research: Less Centralized, Renewable Power a Better Bet as Hurricanes Intensify
A UVA-led team demonstrates that modernizing power grids and using renewable energy will be cheaper than repairing hurricane damage to a centralized, fossil fuel-dependent system.
Looking through the columns of the Rotunda out towards the Lawn as the sun sits high in the sky
Research & Discovery
UVA Honors Distinguished Researchers at Virtual Awards Event
In a difficult year, these researchers stood out – and the University recognized them Friday at an online ceremony.
Hla Kyi, getting vaccinated by a fellow UVA Health Employee
Research & Discovery
Why mRNA Vaccines Need Two Doses to Best Work – and What Delays Might Mean
Editor’s Note: Dr. William Petri, a chaired professor of infectious diseases and international health at the University of Virginia and vice chair for research in the Department of Medicine, wrote this piece for The Conversation. His lab is studying the effects of COVID-19 on the immune system and seeking new treatments. With the U.S. facing vaccination delays because of worker shortages and distribution problems, federal health officials now say it’s OK to push back the second dose of the two-part vaccine by as much as six weeks.As an infectious disease doctor, I’ve been fielding a lot of questions from my patients as well as my friends and family about whether the COVID-19 vaccine will still work if people are late receiving their second dose.Why You Need Two Doses 3-4 Weeks ApartTwo doses, separated by three to four weeks, is the tried-and-true approach to generate an effective immune response through vaccination – not just for COVID, but for hepatitis A and B and other diseases as well.The first dose primes the immune system and introduces the body to the germ of interest. This allows the immune system to prepare its defense. The second dose, or booster, provides the opportunity for the immune system to ramp up the quality and quantity of the antibodies used to fight the virus.In the case of the Pfizer and Moderna COVID-19 vaccines, the second dose increases the protection afforded by the vaccine from 60% to approximately 95%.Why the CDC Decided Receiving the Second Dose Within 42 Days Is OKIn the clinical trial, the second dose of the Pfizer vaccine was administered as early as day 19 and as late as day 42 to 93% of the subjects. Since protection was approximately 95% for everyone who was vaccinated within this time “window,” there is little reason not to allow some flexibility in the timing of the second dose.As more vaccine becomes available, the timing of the second dose should be close to four weeks for the Pfizer and Moderna vaccines. But the good news is that even while supplies remain limited, the science suggests that there’s nothing bad about getting a second dose as late as 42 days after the first.What the Immune System Does Between the First and Second DoseThe biology through which the mRNA vaccines induce their protection from COVID-19 is fundamentally different from that with other vaccines.Pfizer and Moderna vaccines use messenger RNA that encodes the spike glycoprotein. Upon injection of the vaccine, the mRNA enters into immune cells called dendritic cells. The dendritic cells use the instructions written in the mRNA to synthesize the hallmark spike glycoprotein, which characterizes the SARS-CoV-2 virus that causes COVID-19. These immune cells then show the spike glycoprotein to B-cells, which then make anti-spike antibodies.Dendritic cells recognize viruses and present information about the spike protein to T-cells. T-cells provide information about the viral spike protein to B-cells, which are transformed to memory B-cells that store information about the virus. When this memory B-cell is activated with an infection or the second dose of the vaccine, this causes some of the B-cells to change into plasma B-cells that secrete protective antibodies that fight the virus. The mRNA vaccines are uniquely capable of inducing a special kind of immune cell – called a T-follicular helper cell – to help B-cells produce antibodies. The T-cells do this through direct contact with the B-cells and by sending chemical signals that tell the B-cells to produce antibodies. It is this help in antibody production that makes these vaccines so effective.But not all B-cells are the same. There are two kinds that make anti-spike antibodies: long-lived plasma cells and memory B-cells. The long-lived plasma cells, as their name implies, live in the bone marrow for years after vaccination, continuously churning out antibody – in this case anti-spike antibody. These long-lived B-cells do not need to be boosted.The memory B-cells, on the other hand, live in a state akin to hibernation. They do not produce antibodies until stimulated by a booster of the vaccine, or are exposed to infection with the coronavirus that causes COVID-19. That is the reason we need that second dose. Together these two types of B-cells provide a constant level of protection.What Happens if You Don’t Get the Pfizer or Moderna Second Dose On Time?With current vaccine shortages, and problems with setting up the infrastructure to vaccinate millions of people, many physicians are concerned that the second dose of vaccine won’t be delivered in the prescribed three- to four-week window.That booster shot is necessary for the T-cells to stimulate the memory B-cells to produce massive quantities of antibodies. If the booster isn’t given within the appropriate window, lower quantities of antibodies will be produced that may not provide as powerful protection from the virus.

Pagination

  • Show more
University of Virginia Logo
  • Linkedin Icon YouTube
  • X Icon X
  • Facebook Icon Facebook
  • Instagram Icon Instagram
  • Linkedin Icon Linkedin
  • Threads Icon Threads

UVA About Us

  • About Us
  • News Releases
  • Privacy Policy
  • Contact
© 2025 By The Rector And Visitors Of The University Of Virginia